Glatiramer acetate controlled release - Mapi Pharma

Drug Profile

Glatiramer acetate controlled release - Mapi Pharma

Alternative Names: GA Depot; GA long-acting injection; Glatiramer acetate depot formulation - Mapi Pharma; Glatiramer acetate long-acting formulation - Mapi Pharma; Glatiramer acetate microspheres

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mapi Pharma
  • Class Peptides; Polymers
  • Mechanism of Action MHC class II gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 17 Aug 2017 Mapi Pharma completes a phase IIa trial in Multiple sclerosis (Recurrent) in Israel (NCT02212886)
  • 08 Aug 2017 Glatiramer acetate controlled release is still in phase II trials for Multiple sclerosis in Israel (IM) (Mapi Pharma pipeline, August 2017)
  • 08 Aug 2017 Mapi Pharma announces intention to submit a marketing application under the 505(b) regulatory pathway to US FDA for Multiple sclerosis in 00 (Mapi Pharma pipeline, August 017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top